Physician profile
Janet Neigel
NPI 1487698163
$89,913.70
in general payments reported to CMS, 2019-2025
12 companies · $582 in 2025
The $582 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,678 · 2020: $30K · 2021: $22K · 2022: $8,851 · 2023: $17K · 2024: $1,281 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $14K · Food and Beverage: $3,619 · Travel and Lodging: $1,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $13,718.75 |
| Food and Beverage | $3,618.79 |
| Travel and Lodging | $1,936.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $44,885.87 | 2019-2023 | Tepezza |
| Galderma Laboratories, L.P. | $41,697.83 | 2019-2025 | |
| Amgen INC. | $959.14 | 2024-2025 | Tepezza |
| Abbvie INC. | $953.57 | 2023-2025 | |
| Allergan, INC. | $780.66 | 2019-2022 | |
| Revance Therapeutics, INC. | $401.36 | 2024-2025 | Daxxify |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.99 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $56.57 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $29.03 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Acelrx Pharmaceuticals, INC. | $15.28 | 2022 | |
| Argenx US, INC. | $15.00 | 2025 | Vyvgart Hytrulo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Neigel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.